<DOC>
	<DOCNO>NCT00461786</DOCNO>
	<brief_summary>The primary purpose trial estimate drug effect tumor patient ovarian primary peritoneal cancer . Patients receive Pemetrexed every 21 day disease progression unacceptable toxicity . This medication give 10 minute may administer intravenously ( IV ) , vein arm . Vitamin supplementation require part study .</brief_summary>
	<brief_title>A Study Single Agent Pemetrexed Disodium Treating Patients With Recurrent Persistent Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm recurrent persistent disease ovarian epithelial primary peritoneal cancer Measurable disease Must receive 1 prior platinumbased ( carboplatin , cisplatin , another organoplatinum compound ) chemotherapy regimen primary disease . Patients receive prior paclitaxel may receive second regimen include paclitaxel Treatmentfree interval &lt; 6 month prior platinumbased therapy OR progress platinumbased therapy Not eligible high priority Gynecologic Oncology Group ( GOG ) protocol ( i.e. , active phase III GOG protocol patient population ) Patients prior therapy pemetrexed Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence malignancy present within last five year . Patients also exclude previous cancer treatment contraindicate protocol therapy . Patients receive radiation 25 % marrow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>